PamGene International B.V.

To introduce PamGene to you, I would say that it is one of the most innovative companies in the Netherlands translating its solid microarray technologies, with the theme of fast multi-marker testing into complete products. With this approach we are targeting a selected but substantial group of customers that are active in the Life Sciences Industry. We are anchored in science and business through the support of an array of international well-known scientists and universities as well as through commercial relations with first class companies such as Olympus, Innogenetics and JPT Peptide Technologies I’m proud that the company’s growth has been achieved through strong collaboration with our advisors and customers. Helped by this strong scientific and end-user involvement we are bringing full solutions to the areas of drug development and diagnostics. Innovative applications in the fields of predictive toxicology and kinase inhibitor testing were developed in parallel with the end-development of our PamStation™ 4 and PamStation™ 96 instruments.
PamGene can be seen as a two-sided company with products both in diagnostics and pharmaceutical laboratories. It is clear to me that to have the insights into healthcare from both the treatment and the testing sides, gives PamGene a unique position to further invent and develop the best products for both areas. The emerging need for personalized healthcare as well as the clear trend to enhance wellbeing will benefit from such insights.
I hope you have an informative visit to our website and I would like to invite you to contact or visit us at our facilities in ‘s-Hertogenbosch, The Netherlands.

Contact Details: P.O. Box 1345 BJ 's-Hertogenbosch 5200 Netherlands Tel: 31(0)73 615 8080 Fax: 31 (0)73 615 8081 Email: info@pamgene.com WWW: www.pamgene.com/

BioNews Results for PamGene International B.V.:
Good Neurocognitive Performance Measured by the International HIV Dementia Scale in Early HIV-1 Infection	JAIDS:  Nov 13 2009 2:20AM Matching: international b
Results From Chelsea Therapeutics' Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension to be Pr	Pharma Live:  Nov 13 2009 12:22AM Matching: international b
Cytokinetics Announces Non-Clinical Data Relating to GSK-923295 to Be Presented at the 2009 AACR-NCI-EORTC Int	Pharmacy Choice:  Nov 13 2009 6:26AM Matching: international b
Cytokinetics Announces Non-Clinical Data Relating to GSK-923295 to Be Presented at the 2009 AACR-NCI-EORTC Int	Genetic Engineering News:  Nov 13 2009 12:13AM Matching: international b
Results From Chelsea Therapeutics' Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension to be Pr	Therapeutics Daily:  Nov 12 2009 1:32PM Matching: international b
Promote your company here: BioNewsCast - Press Release Distribution	→View more PamGene International B.V. news.

PamGene International B.V. Patents:
US Patent No.	Title
6886409	System for controlling the flow of a fluid through a substrate
6864102	Device for performing an assay, a method for manufacturing said device, and use of a membrane in the manufacture of said device
6855539	Device for performing an assay, a method for manufacturing said device, and use of a membrane in the manufacture of said device

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 227 times since April 2007, the link to the organisation's website has been followed 49 times

Search for more companies in BJ 's-Hertogenbosch

Search for more companies in

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for PamGene International B.V.